Insulet Corporation · NASDAQ (us_market)
Healthcare · Medical Devices · United States
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-05-20$327.47 RISE2025-08-06$277.30 PEAK2025-09-09$352.82 112d | -15.3% 78d | Missed | Missed | — | — | +27.2% 34d | Missed |
DROP2025-02-20$288.29 RISE2025-04-21$238.57 PEAK2025-05-20$327.47 89d | -17.2% 60d | Missed | Missed | — | — | +37.3% 29d | Missed |
DROP2025-02-20$288.29 RISE2025-03-10$237.06 PEAK2025-05-20$327.47 89d | -17.8% 18d | Missed | Missed | — | — | +38.1% 71d | Missed |
DROP2024-01-11$207.55 RISE2024-05-13$161.02 PEAK2024-06-27$206.98 168d | -22.4% 123d | 2024-02-28 $163.60 | 2024-06-27 $206.98 | 56Quality on Sale | 48Watch | +28.5% 45d | +26.5% Held 120d |
DROP2023-12-27$221.42 RISE2024-04-04$163.25 PEAK2024-06-27$206.98 183d | -26.3% 99d | 2024-02-28 $163.60 | 2024-06-27 $206.98 | 56Quality on Sale | 48Watch | +26.8% 84d | +26.5% Duplicate trade Held 120d |
DROP2023-06-26$296.74 RISE2023-10-12$127.77 PEAK2023-12-27$221.42 184d | -56.9% 108d | Missed | Missed | — | — | +73.3% 76d | Missed |
DROP2022-08-25$282.86 RISE2022-10-20$212.22 PEAK2022-11-04$313.00 71d | -25.0% 56d | Missed | Missed | — | — | +47.5% 15d | Missed |
DROP2022-04-01$279.02 RISE2022-05-11$186.40 PEAK2022-08-05$267.05 126d | -33.2% 40d | Missed | Missed | — | — | +43.3% 86d | Missed |
DROP2021-11-09$318.29 RISE2022-03-14$211.96 PEAK2022-04-01$279.02 143d | -33.4% 125d | Missed | Missed | — | — | +31.6% 18d | Missed |
DROP2021-11-09$318.29 RISE2022-01-27$194.80 PEAK2022-04-01$279.02 143d | -38.8% 79d | Missed | Missed | — | — | +43.2% 64d | Missed |
DROP2021-04-27$304.06 RISE2021-05-12$225.52 PEAK2021-07-06$286.77 70d | -25.8% 15d | Missed | Missed | — | — | +27.2% 55d | Missed |
DROP2021-01-20$293.05 RISE2021-03-08$235.95 PEAK2021-04-27$304.06 97d | -19.5% 47d | Missed | Missed | — | — | +28.9% 50d | Missed |
DROP2020-05-11$224.73 RISE2020-06-04$172.98 PEAK2020-08-06$220.42 87d | -23.0% 24d | Missed | Missed | — | — | +27.4% 63d | Missed |
DROP2020-02-20$216.44 RISE2020-03-18$130.01 PEAK2020-05-11$224.73 81d | -39.9% 27d | Missed | Missed | — | — | +72.9% 54d | Missed |
Insulet, ticker NasdaqGS:PODD, has issued a voluntary medical device correction for certain Omnipod insulin pods due to a manufacturing defect. The defect can cause insulin leakage and under-delivery, which has been linked to serious adverse health events such as diabetic ketoacidosis. The company is working to replace affected pods globally and has implemented corrective actions in its manufacturing process. For investors tracking NasdaqGS:PODD, this correction is a material operational...
Insulet earns a short-term Hold as outlook rises; a $163 sales-based target tests whether growth can beat 2026 volatility.
Boston Scientific (BSX) previously commanded a premium valuation based on its transition toward a high-margin cardiovascular powerhouse, driven by its FARAPULSE Pulsed Field Ablation (PFA) system and WATCHMAN cardiac implant. In Q1 2026, the cardiovascular segment posted a strong 13.5% reported growth. However, intense competition from Medtronic (MDT) and Johnson & Johnson (JNJ) has challenged this hyper-growth thesis. Johnson & Johnson's Varipulse system integrates directly into the dominant CA
Insulet Corporation (NASDAQ:PODD) is one of the best medical technology stocks to buy right now. On May 20, William Blair analyst Steve Lichtman assumed coverage of Insulet Corporation (NASDAQ:PODD) with an Outperform rating. Lichtman argued that Insulet’s steep selloff has created an appealing entry point despite risks to its near‑term growth outlook. The analyst highlighted […]
Insulet's Omnipod 5 drives a Q1 beat and raised 2026 outlook as upgrades and global rollout expand access - while correction costs loom.
The recall is Insulet’s second this year related to tears in the device tubing. So far, 24 serious adverse events have been reported.
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session.
ACTON, Mass., May 26, 2026--Insulet Corporation, Inc. (NASDAQ: PODD) ("Insulet" or the "Company") today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery.
Insulet Corporation, Inc. (NASDAQ:PODD) ("Insulet" or the "Company") today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH®, and Omnipod® Insulin Management
The device called Mint, which would work with the company’s adaptive insulin dosing algorithm, is expected to debut in the first half of 2027.
The device called Mint, which would work with the company’s adaptive insulin dosing algorithm, is expected to debut in the first half of 2027.
Although Insulet has lagged the broader market over the past year, Wall Street analysts remain strongly optimistic about the company’s long-term growth prospects.
Although Insulet has lagged the broader market over the past year, Wall Street analysts remain strongly optimistic about the company’s long-term growth prospects.
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
Alpha Wealth Funds, LLC, an investment management company, released its Q1 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here. The fund lost 7.14% in the quarter, tied to a 6.75% fall in March due to the War in Iran. This compares to the S&P 500’s -4.33% return for […]
Alpha Wealth Funds, LLC, an investment management company, released its Q1 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here. The fund lost 7.14% in the quarter, tied to a 6.75% fall in March due to the War in Iran. This compares to the S&P 500’s -4.33% return for […]
The average S&P 500 stock gained 35% in the year leading up to the index's most recent all-time closing high made last Thursday (5/14).
Boston Scientific (BSX) stock declined 47% over the last 12 months to trade near $57. Despite total revenues growing 17.4% to $20.6 billion and net income margins improving to 17.3%, the P/E multiple contracted by 70%. The selloff was triggered by a Q4 2025 GAAP EPS miss and a significant full-year 2026 organic growth guidance cut. The company's management lowered the target from a 10 to 11% range down to 6.5 to 8.0%, attributing the reset to greater-than-expected market share loss in the Electr
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| PODD | -17.20% | -40.95% | -49.01% | -55.41% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -20.17% | -35.23% | -45.56% | -68.10% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 3.97M | $834.05M | 0.04% | Trimmed-37.2% | 2026-03-31 |
| StateStreet | passive | 3.04M | $638.43M | 0.02% | Trimmed-3.6% | 2026-03-31 |
| CapResearch | fundamental | 1.67M | $350.33M | 0.05% | Trimmed-62.1% | 2026-03-31 |
| TwoSigma | quant | 762.3K | $159.97M | 0.13% | Added+107.9% | 2026-03-31 |
| RenTech | quant | 426.0K | $89.39M | 0.14% | Added+40.5% | 2026-03-31 |
| DEShaw | quant | 133.6K | $28.03M | 0.02% | Added+377.1% | 2026-03-31 |
| Wellington | fundamental | 107.8K | $22.61M | 0.00% | Trimmed-3.2% | 2026-03-31 |
| Bridgewater | macro | 35.3K | $7.41M | 0.03% | Trimmed-38.4% | 2026-03-31 |
| TRowePrice | fundamental | 282.6K | $59.31K | 0.01% | Added+2.4% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-21 | BORIO LUCIANA | Director | A Grant / award | 1,660 | — | +$0 |
| 2026-05-21 | Frederick Wayne A.I. | Director | A Grant / award | 1,660 | — | +$0 |
| 2026-05-21 | Hopfield Jessica | Director | A Grant / award | 1,660 | — | +$0 |
| 2026-05-21 | Huffines Robert Luther | Director | A Grant / award | 1,660 | — | +$0 |
| 2026-05-21 | MINOGUE MICHAEL R | Director | A Grant / award | 1,660 | — | +$0 |
| 2026-05-21 | Scannell Timothy J | Director | A Grant / award | 1,660 | — | +$0 |
| 2026-05-21 | STONESIFER TIMOTHY C. | Director | A Grant / award | 1,660 | — | +$0 |
| 2026-05-21 | WEATHERMAN ELIZABETH H | Director | A Grant / award | 1,660 | — | +$0 |
| 2026-05-15 | McEvoy Ashley | President and CEO | F Tax withholding | 1,411 | $148.84 | −$210.0K |
| 2026-04-02 | Huffines Robert Luther | Director | A Grant / award | 111 | $209.84 | +$23.3K |
| 2026-04-02 | Panos Michael | EVP and CCO | A Grant / award(deriv) | 7,255 | — | +$0 |
| 2026-04-02 | Panos Michael | EVP and CCO | A Grant / award | 2,777 | — | +$0 |
| 2026-03-03 | Benjamin Eric | EVP and COO | F Tax withholding | 268 | $246.61 | −$66.1K |
| 2026-03-03 | Benjamin Eric | EVP and COO | F Tax withholding | 644 | $246.61 | −$158.8K |
| 2026-03-03 | Kapples John W. | SVP and General Counsel | F Tax withholding | 194 | $246.61 | −$47.8K |
| 2026-03-03 | Kapples John W. | SVP and General Counsel | F Tax withholding | 411 | $246.61 | −$101.4K |
| 2026-03-03 | Budden Lauren | Group VP, CAO and Controller | F Tax withholding | 99 | $246.61 | −$24.4K |
| 2026-03-03 | Budden Lauren | Group VP, CAO and Controller | F Tax withholding | 119 | $246.61 | −$29.3K |
| 2026-03-03 | Cousin Laetitia | SVP, Reg, Quality & Compliance | F Tax withholding | 53 | $246.61 | −$13.1K |
| 2026-03-03 | Cousin Laetitia | SVP, Reg, Quality & Compliance | F Tax withholding | 200 | $246.61 | −$49.3K |
| 2026-03-03 | Singh Prem | SVP, Global Operations | F Tax withholding | 62 | $246.61 | −$15.3K |
| 2026-03-03 | Singh Prem | SVP, Global Operations | F Tax withholding | 207 | $246.61 | −$51.0K |
| 2026-02-26 | MINOGUE MICHAEL R | Director | P Open-market purchase | 2,030 | $246.23 | +$499.8K |
| 2026-02-26 | McEvoy Ashley | President and CEO | A Grant / award(deriv) | 26,143 | — | +$0 |
| 2026-02-26 | McEvoy Ashley | President and CEO | A Grant / award | 10,046 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | 1.45 | — | — |
| 2026-05-06 | 1.16 | 1.30 | +11.89% |
| 2026-02-18 | 1.46 | 1.55 | +5.97% |
| 2025-11-06 | 1.15 | 1.24 | +8.07% |
| 2025-08-07 | 0.92 | 1.17 | +26.81% |
| 2025-05-08 | 0.79 | 1.02 | +29.70% |
| 2025-02-20 | 1.02 | 1.15 | +12.63% |
| 2024-11-07 | 0.76 | 0.90 | +18.29% |
| 2024-08-08 | 0.56 | 0.55 | -2.53% |
| 2024-05-09 | 0.39 | 0.73 | +85.10% |
| 2024-02-22 | 0.66 | 1.40 | +111.44% |
| 2023-11-02 | 0.41 | 0.71 | +73.76% |
| 2023-08-08 | 0.26 | 0.38 | +43.41% |
| 2023-05-04 | 0.10 | 0.23 | +122.18% |
| 2023-02-23 | 0.19 | 0.55 | +188.90% |
| 2022-11-03 | 0.14 | 0.41 | +194.26% |